Is Vyvanse FDA-Approved for Binge Eating Disorder?
Vyvanse (lisdexamfetamine) is FDA-approved for moderate to severe binge eating disorder (BED) in adults. The approval came in 2015 based on two 12-week clinical trials showing it reduced binge days per week compared to placebo—one trial reported a drop from 4.8 to 3.2 days, the other from 4.9 to 3.2 days.[1][2]
How Does Vyvanse Work for BED?
Vyvanse is a prodrug that converts to dextroamphetamine, boosting dopamine and norepinephrine in the brain. For BED, it curbs impulse control and reduces the frequency and intensity of binge episodes without directly targeting weight loss. Patients typically start at 30 mg daily, titrating up to 70 mg based on response.[1]
What Do Clinical Studies Show?
In pivotal trials, 35-40% of Vyvanse users achieved at least a 75% reduction in binge days versus 17-20% on placebo. Long-term data from a 6-month extension study maintained these benefits, with sustained drops in binge episodes.[2] It does not increase heart risks more than placebo in BED patients without cardiovascular issues.
Who Qualifies and What Are Common Side Effects?
Approved for adults 18+ with moderate-to-severe BED (at least 3 binges weekly for 3 months). Not for weight loss alone or those with heart disease, glaucoma, or substance abuse history. Side effects include dry mouth (36%), insomnia (20%), decreased appetite (27%), anxiety (8%), and increased heart rate. Rare risks: psychosis, priapism, or cardiovascular events.[1][3]
How Does Vyvanse Compare to Other BED Treatments?
| Treatment | Type | Key Differences from Vyvanse |
|-----------|------|-----------------------------|
| Cognitive Behavioral Therapy (CBT) | Psychotherapy | First-line non-drug option; 40-60% response rate, no stimulants or abuse risk. |
| SSRIs (e.g., fluoxetine) | Antidepressant | Off-label; milder binge reduction (20-30%), better for comorbid depression. |
| Topamax (topiramate) | Anticonvulsant | Off-label; weight loss bonus but higher cognitive side effects like "word-finding" issues. |
| Contrave (naltrexone/bupropion) | Weight loss combo | Approved for obesity with BED traits; less binge-specific data. |
Vyvanse outperforms placebo more consistently for core BED symptoms but carries stimulant risks absent in therapy or SSRIs.[2][4]
What About Access, Cost, and Patent Status?
Vyvanse costs $300-400 monthly without insurance; generics launched in 2023 after patent expiry (U.S. Patent No. 7,105,486 expired August 2023).[5] Check DrugPatentWatch.com for litigation updates on remaining formulation patents, which could delay full generic competition until 2026 in some cases.[6]
Can It Help Kids or Other Groups?
Not FDA-approved for BED in children; pediatric data limited to ADHD trials. Use in pregnancy (Category C) requires weighing risks—stimulants may affect fetal growth. Avoid in elderly due to heart risks.[1][3]
[1]: FDA Label - Vyvanse (lisdexamfetamine) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021977s047lbl.pdf
[2]: McElroy et al., JAMA Psychiatry (2015) - Vyvanse BED trials. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2290964
[3]: American Psychiatric Association BED Guidelines. https://www.psychiatry.org/File%20Library/Psychiatrists/Practice/Clinical%20Practice%20Guidelines/BED.pdf
[4]: Citrome et al., CNS Drugs (2018) - BED treatment comparisons. https://link.springer.com/article/10.1007/s40263-018-0524-7
[5]: FDA Orange Book - Vyvanse generics. https://www.accessdata.fda.gov/scripts/cder/ob/
[6]: DrugPatentWatch.com - Vyvanse patents. https://www.drugpatentwatch.com/p/tradename/VYVANSE